Reciprocal changes of serum adispin and visfatin levels in patients with type 2 diabetes after an overnight fast

Archives of Endocrinology and Metabolism

Volumn 60, Issue 1, 2016, Pages 76-78

  Legakis, Ioannis ^a   Mantzouridis, Timos ^b   Bouboulis, George ^c   Chrousos, George P ^d  

^a IASO GENERAL HOSPITAL   (Greece)

^b Euromedica Inst of High Technology   (Greece)

^c UNIVERSITY OF ATHENS   (Greece)

^d UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Adipsin; Fasting; Humans; Type 2 diabetes; Visfatin

Indexed keywords

COMPLEMENT FACTOR D; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE;

AGED; BLOOD; CASE CONTROL STUDY; DIET RESTRICTION; FEMALE; GLUCOSE TOLERANCE TEST; HUMAN; MALE; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COMPLEMENT FACTOR D; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; MALE; MIDDLE AGED; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE;

EID: 84988904318     PISSN: 23593997     EISSN: 23594292     Source Type: Journal    
DOI: 10.1590/2359-3997000000147     Document Type: Article

References (9)

1. Trujillo ME, Scherer PE. Adipose tissue-derived factors: impact on health and disease. Endocr Rev. 2006;27(7):762-78.
2. Lee JO, Kim N, Lee HJ, Lee YW, Kim JK, Kim HI, et al. Visfatin, a novel adipokine, stimulates glucose uptake through the Ca2 +-dependent AMPK-p38 MAPK pathway in C2C12 skeletal muscle cells. J Mol Endocrinol. 2015;54(3):251-62.
3. Lo JC, Ljubicic S, Leibiger B, Kern M, Leibiger IB, Moede T, et al. Adipsin is an adipokine that improves β cell function in diabetes. Cell. 2014;158(1):41-53.
4. Flier JS, Cook KS, Usher P, Spiegelman BM. Severely impaired adipsin expression in genetic and acquired obesity. Science. 1987;237(4813):405-8.
5. Platt AK, Min YH, Ross RS, Spiegelman BM. Obesity-linked regulation of the adipsin gene promoter in transgenic mice. Proc Nadl Acad Sci. 1989;86(19):7490-4.
6. Esteghamati A, Alamdari A, Zandieh A, Elahi S, Khalilzadeh O, Nakhjavani M, et al. Serum visfatin is associated with type 2 diabetes mellitus independent of insulin resistance and obesity. Diabetes Res Clin Pract. 2011;91(2):154-8.
7. Chang YH, Chang DM, Lin KC, Shin SJ, Lee YJ. Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta-analysis and systemic review. Diabetes Metab Res Rev. 2011;27(6):515-27.
8. Amato MC, Pizzolanti G, Torregrossa V, Misiano G, Milano S, Giordano C. Visceral adiposity index (VAI) is predictive of an altered adipokine profile in patients with type 2 diabetes. PLoS One. 2014;9(3):e91969.
9. Schwingshackl L, Missbach B, Dias S, König J, Hoffmann G. Impact of different training modalities on glycaemic control and blood lipids in patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetologia. 2014;57(9):1789-97.